Shorts are about 30% of tlry. They are trying hard to cover after hours and tomorrow before the bi-monthly short numbers come out. They just don't want the retail investors of $tlry and $apha to know about this.
I for one I'm happy to see the writedowns are out of the way prior to the merger. EBITA has been only positive for more then a year and synergies will run to start with 100 million per year not counting Sweetwater and then other companies under $tlry hehehe :)
If you are having trouble voting for The merger $tlry / $apha you can go in your brokerage site and click services or whatever like you need and you can vote right from there in most cases. You can call your broker and he will walk you through the steps.
Aphria is set to complete its merger with Tilray TLRY, -0.05% this quarter, creating the world’s largest cannabis company by revenue. The combined company will push into the U.K., Sweden, Poland, Luxembourg, and China, with deal discussions ongoing in India, Aphria said.
The expansion in Europe will come in a few weeks at the earliest, when Tilray will begin distributing in Luxembourg, with $APHA and $TLRY businesses pushing into Poland by the third quarter of this year.
Tilray $tlry is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Tilray was the first licensed producer of medical cannabis in the world to have its facility Good Manufacturing Practices (GMP) certified in accordance with European Medicine Agency (EMA) standards.
The company currently serves tens of thousands of patients, physicians, pharmacies, governments, hospitals, and researchers in eight countries spanning four continents through its affiliated entities in Australia and New Zealand (Tilray Australia New Zealand Pty Ltd), Canada (Tilray Canada Ltd), Germany (Tilray Deutschland GmbH), and Portugal (Tilray Portugal Unipessoal Lda).
$APHA & $TLRY already at break even levels looking forward with revenues on a steady rise. After the merger are complete net earnings will be a solid green with analyst recognizing growth and synergies.
Paid bashers avoid talking about the business itself for a reason.
MedMen is performing well beyond the levels they were at back when the stock was heavily marketed media-darling. Retail profitability was a pipedream back then, whereas today, we're headed into the 3rd quarter straight of successive increases and positive cashflow.
Consider this: California isn't locked down anymore, meaning foot-traffic will be driving sales again. Now add the growth we've seen from the highly efficient new mobile marketing strategy, industry leading "scheduled" deliveries and the market-share they gained from their absolutely flawless curbside pick-up operations and I expect Q3 to turn public sentiments in MedMen's favor like never before.
So if the stock finished over .40 today, I would have told all my friends to buy now because it's still oversold and has a lot of room to fly.. so imagine what I'm saying now? "It's a steal."
Some short term traders and weak-hands took profits today, good for them, but the longs are not selling.. they know the risk of missing the next parabolic rise to $1+ isn't worth the pennies gained from going in and out anymore.
As for myself, I'm in full on accumulation mode... cost basis is already lower than my original entry, and I'm firmly in the green. Wouldn't even think about selling more than 20% of my holding until we're uplisted to NYSE or NASDAQ, and comfortablly trading in the double digits with peers like $APHA, $CGC and $TLRY
Aphria + Tilray quarterly sales $120.5 USD
$CURLF has dispensaries in the US as do $CRLBF $GTBIF $TRSSF $TCNNF $VREOF.
$APHA $TLRY do not.
This is why merger is cancelled. Tilray wants a better US partner.
Aphria + Tilray quarterly sales $120.5 USD
$CURA has dispensaries in the US as do $CRLBF $GTBIF $TRSSF.
$APHA $TLRY do not.
Now you tell me where the better investment is.
YES OF COURSE AND ESPECIALLY AT THESE LOLO PRICES.
Thank you shorts this helps me average down for the boomerang effect :-)
Going back to $300 PPS and the institutions will be working with the retail investors on this one hahaha hehehe :-)
4/8/21, 9:03 AM
Mc should be higher than Cura and Canopy.
The expansion in Europe will come in a few weeks at the earliest, when Tilray will begin distributing in Luxembourg, with $APHA and $TLRY businesses pushing into Poland by the third quarter of this year.
See that guys? Actual THC products being sold within the USA! No CBD only Granny Water like $APHA $TLRY 🤣🤣🤣🤣🤣
Market Caps
Tilray: $7.42bn
Cura: $9.65bn
Canopy: $10.51bn
has to correct soon. 🇺🇸🇨🇦
The company currently serves tens of thousands of patients, physicians, pharmacies, governments, hospitals, and researchers in eight countries spanning four continents through its affiliated entities in Australia and New Zealand (Tilray Australia New Zealand Pty Ltd), Canada (Tilray Canada Ltd), Germany (Tilray Deutschland GmbH), and Portugal (Tilray Portugal Unipessoal Lda).
going up into the merger. Merger vote today after close. 🇺🇸🇨🇦
MedMen is performing well beyond the levels they were at back when the stock was heavily marketed media-darling. Retail profitability was a pipedream back then, whereas today, we're headed into the 3rd quarter straight of successive increases and positive cashflow.
Consider this: California isn't locked down anymore, meaning foot-traffic will be driving sales again. Now add the growth we've seen from the highly efficient new mobile marketing strategy, industry leading "scheduled" deliveries and the market-share they gained from their absolutely flawless curbside pick-up operations and I expect Q3 to turn public sentiments in MedMen's favor like never before.
So if the stock finished over .40 today, I would have told all my friends to buy now because it's still oversold and has a lot of room to fly.. so imagine what I'm saying now? "It's a steal."
Some short term traders and weak-hands took profits today, good for them, but the longs are not selling.. they know the risk of missing the next parabolic rise to $1+ isn't worth the pennies gained from going in and out anymore.
As for myself, I'm in full on accumulation mode... cost basis is already lower than my original entry, and I'm firmly in the green. Wouldn't even think about selling more than 20% of my holding until we're uplisted to NYSE or NASDAQ, and comfortablly trading in the double digits with peers like $APHA, $CGC and $TLRY
https://seekingalpha.com/instablog/53884982-ryan-lynk/5574565-hedge-and-mutual-funds-are-buying-aphria-striking-rate